TABLE 5.

TEAEs by preferred term that were reported in one or more subjects in either treatment group in the safety population

Adverse event	No. (%) of subjects with each adverse event who were given:
	Omadacycline (n = 42)	Tigecycline (n = 21)
Subjects with at least one TEAE	12 (28.6)	11 (52.4)
Headache	5 (11.9)	3 (14.3)
Epistaxis	2 (4.8)	2 (9.5)
Nausea	1 (2.4)	10 (47.6)
Decreased appetite	0	2 (9.5)
Vomiting	0	3 (14.3)
Subjects with any TEAE leading to study drug discontinuation	0	2 (9.5)
Nausea	0	2 (9.5)
Subjects with any serious TEAE	0	0